PGNY

In the past six months (April-October 2026), Progyny's stock experienced several notable events. On October 7, 2026, the stock jumped 6% after the company announced its annual selling season was pacing to a record level, expecting to add 1.2 million new covered lives for launches in the first half of 2027. On August 6, 2026, Progyny reported strong Q2 2026 results with 5.3% year-over-year revenue growth (11% excluding Amazon), a 13% increase in gross profit, a 7.2% rise in adjusted EBITDA, and an adjusted EPS of $0.55, surpassing analyst estimates. In July 2026, the stock reached a 52-week high of $32.36. However, around April 2026, the stock dropped 22% due to a weak financial outlook for 2026, as Q1 revenue guidance and full-year adjusted EPS and EBITDA guidance fell short of analyst expectations. The company also made presentations at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, and the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. Overall, the stock price increased by 3.14% in the past month and 8.76% year-to-date, reaching $25.23 as of October 2, 2026, a 22.54% increase from October 3, 2025.